Shopping Cart 0
Cart Subtotal
USD 0

COVID-19 Impact on Global Peptic Ulcer Drugs Market by Disease Indication (Gastric Ulcers, Duodenal Ulcers, and Esophageal Ulcers); By Application (Hospital Pharmacies, Drug Stores, Retail Stores and Online Sales) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

Bundle Purchase

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option : NO
Copy Option : No
Download Option: No
Deliverable Format : Excel viewable on the website via username

Excel Only
USD 2800

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 3850

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 7500

Details

Product Overview

Gastrointestinal conditions such as gastritis, gastric ulcers, and duodenal ulcers or gastroesophageal reflux disease (GERD) are referred to as peptic ulcers. Drugs used to treat peptic ulcers include drugs that decrease the secretion of gastric ulcers, such as antagonists of the PPI and H2 receptors and acid neutralization agents such as antacids and antibiotics against H. Pylori. These medications, however, are also used in conjunction for successful treatment.

Market Highlights

Global Peptic Ulcer Drugs Market size was registered at USD 4.9 billion in 2019 and is estimated to reach USD 6.8 billion by 2030, registering a CAGR of 3.17 % from 2020 to 2030. Increasing the prevalence of peptic ulcers, increasing the adoption of peptic ulcer drugs over surgery, stimulating R&D through government policies, increasing the number of generic producers of peptic ulcer drugs, improvements in disease management, etc., are factors driving the growth of the global peptic ulcer market. Also, factors such as the increased prevalence of stress-induced ulcers due to changing lifestyle and diet increased smoking rates, and progressive geriatric population are anticipated to facilitate the expansion of the global market for peptic ulcer drugs

                                           Global Peptic Ulcer Drugs Market Opportunity Analysis

                                                 

Source: Fatpos Global

Global Peptic Ulcer Drugs Market: Segments

Peptic Ulcer Drugs Market is segmented based on disease indication, application, and region.

By Disease Indication (in %), Peptic Ulcer Drugs Market, 2019

The gastric ulcers segment is anticipated to register XX% of the market share during the forecasted period.

By disease indication, the market can be segmented into gastric ulcers, duodenal ulcers, and esophageal ulcers. Due to the high prevalence of diseases, the gastric ulcers segment is projected to account for a significant share of the global market during the forecast period.

By Application (in %), Peptic Ulcer Drugs Market, 2019

The hospital pharmacies segment accounted for XX% of the nation’s volume in 2019

The application segment can be classified into hospital pharmacies, drug stores, retail stores, and online sales. The hospital pharmaceuticals segment is projected to dominate the global market due to an increase in hospital numbers and a wide variety of services delivered at a single site.

                                      

Source: Fatpos Global

Global Peptic Ulcer Drugs Market Dynamics:

Increasing research and development and government policies to increase the market growth

Increasing the prevalence of peptic ulcers, increasing the adoption of peptic ulcer drugs over surgery, stimulating R&D through government policies, increasing the number of generic producers of peptic ulcer drugs, improvements in disease management, etc., are factors driving the growth of the global peptic ulcer market. Also, factors such as the increased prevalence of stress-induced ulcers due to changing lifestyle and diet, increased smoking rates, and progressive geriatric population is anticipated to facilitate the expansion of the global market for peptic ulcer drugs. The key driving factors for the drug market for peptic ulcers are stress, ulcers caused by medications, rising incidence of H.Pyrroli infection, improvements in food, increase in cancer, use of tobacco, and alcohol. Patent expiry, a comparatively good treatment regimen of proton pump inhibitors, H.Pyrolli resistance, severe market fragmentation in many businesses and wide generic penetration are constraining factors in this market.

Side effects related to ulcer medications and low efficiency to hinder the market growth

Factors expected to hamper the growth of the global peptic ulcer market over the forecast period are the side effects of peptic ulcer medications, low pipeline efficiency, and shifts in drug pricing policies.

Global Peptic Ulcer Drugs Market: Regions

In terms of value and volume, North America accounted for XX% of total market volume share in 2019

Global market share of peptic ulcer medications has been driven by North America, and this trend is expected to continue over the forecast period. Increased use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and increased awareness of peptic ulcer treatment options are factors that are expected to drive the growth of the North American market for peptic ulcer drugs. The second-largest share of the demand for peptic ulcer drugs in Europe is mainly due to the simple availability of effective treatment options for peptic ulcers in the country.

The region segment can be further divided into five major types including North America, Latin America, Europe, APAC, and MENA.

                                  

Source: Fatpos Global

Global Peptic Ulcer Drugs Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities-o-Y Growth, CAGR – United States and Canada

  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America

  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
  • MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Peptic Ulcer Drugs Market: Impact of COVID-19

Global pandemic COVID-19 has become global stress, not just for human lives, but also for industries across different industry verticals. The COVID-19 disease has infected several million people globally, with an increasing number of active cases daily, the duration of the pandemic is still difficult to predict. Because of the ongoing COVID-19 pandemic-an acute respiratory distress syndrome triggered by the novel coronavirus-the most unparalleled organizational and economic problems have arisen. Also, a substantial amount of time is needed to establish and market successful treatment options for this new COVID-19 pathogen. In the coming quarters of 2020 and 2021, these combined difficulties of infection transmission and treatment are expected to delay the diagnosis and treatment of GI disease. Reduced physician and hospital visits due to prioritization of COVID-19 care for non-essential health problems would hinder market development. Because of the availability of COVID-19 vaccines, the market for peptic ulcer medications is expected to rebound to pre-pandemic market demand in 2021. This will represent the COVID-19 pandemic in terms of recovering developed and emerging economies. Also, local governments prioritize healthcare services to meet the complexities of COVID-19, which is also projected to slow the pace of the demand for peptic ulcer medications in the short term.

Global Peptic Ulcer Drugs Market: Competitive landscape

New technological advancements in the Peptic Ulcer Drugs Market, as well as large production output of the product by key players, are likely to increase the market growth.

Peptic Ulcer Drugs Market: Key players

  • Eumedica
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Takeda Pharmaceutical Co. Ltd.
  • Taiho Pharmaceutical
  • Ferring Pharmaceuticals
  • PharmaKing
  • Zuventus Healthcare
  • Otsuka Holdings
  • Daiichi Sankyo
  • Johnson and Johnson
  • Other prominent players

Global Peptic Ulcer Drugs Market report also contains analysis on:

Peptic Ulcer Drugs Market segments: -

  • By Disease Indication:
    • Gastric ulcers
    • Duodenal ulcers
    • Esophageal ulcers
  • By Application:
    • Hospital Pharmacies
    • Drug stores
    • Retail stores
    • Online sales
  • Peptic Ulcer Drugs Market dynamics
  • Peptic Ulcer Drugs Market size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints
READ MORE

Table Of Content

Scope

Contents        

  1. Executive Summary
  2. Peptic Ulcer Drugs Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  6. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  7. Recent Development, Policies & Regulatory Landscape
  8. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  9. Peptic Ulcer Drugs Market Analysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  10. Peptic Ulcer Drugs Market
    1. Market Size & forecast, 2019A-2030F
      1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11. Peptic Ulcer Drugs Market: Market Segmentation
    1.       By Regions
      1. North America:(U.S. and Canada)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12. Peptic Ulcer Drugs Market: Market Segmentation
    1. By disease indication: Market Share (2020-2030F)
      1. gastric ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. duodenal ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. esophageal ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    2. By application : Market Share (2020-2030F)
      1. hospital pharmacies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. drug stores, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. retail store, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. online sales, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

 

  1. Company Profile
    1. Eumedica
      1. Company Overview
      2.  Company Total Revenue (Financials)
      3.  Market Potential
      4. Global Presence
      5.  Key Performance Indicators
      6. SWOT Analysis
      7.   Product Launch
    2. Takeda Pharmaceutical Co. Ltd.
    3. Taiho Pharmaceutical
    4. Ferring Pharmaceuticals
    5. PharmaKing
    6. Zuventus Healthcare
    7. Otsuka Holdings
    8. Daiichi Sankyo
    9. Johnson and Johnson
    10.  Other prominent players
  2. Consultant Recommendation

**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Licence Rights

  • Single User License:

    Access to the soft copy of the report will be granted to individual user/ Authorized User within the organization. The Authorized User may store, display or archive the information but will not be able to print, copy and use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete/part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. The report will be MAC address protected and will only be accessible on 1 platform.

  •  
  • Hard Copy License:

    The license provides the access to hard copy/ printed copy of the report to the Authorized User only. The report will be delivered to the user on the address provided during making the purchase. The Authorized User may store, display, or archive the information but will not use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. No soft copy access will be provided in this case.

  •  
  • Corporate User License:

    Access to the soft copy of the report will be granted to multiple users within the organization. The users are authorized to store, display, duplicate, archive, print and distribute the information within the organization either electronically or in paper. The users are not authorized to use any information in the report for citation and circulation externally. The users will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Product Overview

Gastrointestinal conditions such as gastritis, gastric ulcers, and duodenal ulcers or gastroesophageal reflux disease (GERD) are referred to as peptic ulcers. Drugs used to treat peptic ulcers include drugs that decrease the secretion of gastric ulcers, such as antagonists of the PPI and H2 receptors and acid neutralization agents such as antacids and antibiotics against H. Pylori. These medications, however, are also used in conjunction for successful treatment.

Market Highlights

Global Peptic Ulcer Drugs Market size was registered at USD 4.9 billion in 2019 and is estimated to reach USD 6.8 billion by 2030, registering a CAGR of 3.17 % from 2020 to 2030. Increasing the prevalence of peptic ulcers, increasing the adoption of peptic ulcer drugs over surgery, stimulating R&D through government policies, increasing the number of generic producers of peptic ulcer drugs, improvements in disease management, etc., are factors driving the growth of the global peptic ulcer market. Also, factors such as the increased prevalence of stress-induced ulcers due to changing lifestyle and diet increased smoking rates, and progressive geriatric population are anticipated to facilitate the expansion of the global market for peptic ulcer drugs

                                           Global Peptic Ulcer Drugs Market Opportunity Analysis

                                                 

Source: Fatpos Global

Global Peptic Ulcer Drugs Market: Segments

Peptic Ulcer Drugs Market is segmented based on disease indication, application, and region.

By Disease Indication (in %), Peptic Ulcer Drugs Market, 2019

The gastric ulcers segment is anticipated to register XX% of the market share during the forecasted period.

By disease indication, the market can be segmented into gastric ulcers, duodenal ulcers, and esophageal ulcers. Due to the high prevalence of diseases, the gastric ulcers segment is projected to account for a significant share of the global market during the forecast period.

By Application (in %), Peptic Ulcer Drugs Market, 2019

The hospital pharmacies segment accounted for XX% of the nation’s volume in 2019

The application segment can be classified into hospital pharmacies, drug stores, retail stores, and online sales. The hospital pharmaceuticals segment is projected to dominate the global market due to an increase in hospital numbers and a wide variety of services delivered at a single site.

                                      

Source: Fatpos Global

Global Peptic Ulcer Drugs Market Dynamics:

Increasing research and development and government policies to increase the market growth

Increasing the prevalence of peptic ulcers, increasing the adoption of peptic ulcer drugs over surgery, stimulating R&D through government policies, increasing the number of generic producers of peptic ulcer drugs, improvements in disease management, etc., are factors driving the growth of the global peptic ulcer market. Also, factors such as the increased prevalence of stress-induced ulcers due to changing lifestyle and diet, increased smoking rates, and progressive geriatric population is anticipated to facilitate the expansion of the global market for peptic ulcer drugs. The key driving factors for the drug market for peptic ulcers are stress, ulcers caused by medications, rising incidence of H.Pyrroli infection, improvements in food, increase in cancer, use of tobacco, and alcohol. Patent expiry, a comparatively good treatment regimen of proton pump inhibitors, H.Pyrolli resistance, severe market fragmentation in many businesses and wide generic penetration are constraining factors in this market.

Side effects related to ulcer medications and low efficiency to hinder the market growth

Factors expected to hamper the growth of the global peptic ulcer market over the forecast period are the side effects of peptic ulcer medications, low pipeline efficiency, and shifts in drug pricing policies.

Global Peptic Ulcer Drugs Market: Regions

In terms of value and volume, North America accounted for XX% of total market volume share in 2019

Global market share of peptic ulcer medications has been driven by North America, and this trend is expected to continue over the forecast period. Increased use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and increased awareness of peptic ulcer treatment options are factors that are expected to drive the growth of the North American market for peptic ulcer drugs. The second-largest share of the demand for peptic ulcer drugs in Europe is mainly due to the simple availability of effective treatment options for peptic ulcers in the country.

The region segment can be further divided into five major types including North America, Latin America, Europe, APAC, and MENA.

                                  

Source: Fatpos Global

Global Peptic Ulcer Drugs Market is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities-o-Y Growth, CAGR – United States and Canada

  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America

  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
  • MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Peptic Ulcer Drugs Market: Impact of COVID-19

Global pandemic COVID-19 has become global stress, not just for human lives, but also for industries across different industry verticals. The COVID-19 disease has infected several million people globally, with an increasing number of active cases daily, the duration of the pandemic is still difficult to predict. Because of the ongoing COVID-19 pandemic-an acute respiratory distress syndrome triggered by the novel coronavirus-the most unparalleled organizational and economic problems have arisen. Also, a substantial amount of time is needed to establish and market successful treatment options for this new COVID-19 pathogen. In the coming quarters of 2020 and 2021, these combined difficulties of infection transmission and treatment are expected to delay the diagnosis and treatment of GI disease. Reduced physician and hospital visits due to prioritization of COVID-19 care for non-essential health problems would hinder market development. Because of the availability of COVID-19 vaccines, the market for peptic ulcer medications is expected to rebound to pre-pandemic market demand in 2021. This will represent the COVID-19 pandemic in terms of recovering developed and emerging economies. Also, local governments prioritize healthcare services to meet the complexities of COVID-19, which is also projected to slow the pace of the demand for peptic ulcer medications in the short term.

Global Peptic Ulcer Drugs Market: Competitive landscape

New technological advancements in the Peptic Ulcer Drugs Market, as well as large production output of the product by key players, are likely to increase the market growth.

Peptic Ulcer Drugs Market: Key players

  • Eumedica
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Takeda Pharmaceutical Co. Ltd.
  • Taiho Pharmaceutical
  • Ferring Pharmaceuticals
  • PharmaKing
  • Zuventus Healthcare
  • Otsuka Holdings
  • Daiichi Sankyo
  • Johnson and Johnson
  • Other prominent players

Global Peptic Ulcer Drugs Market report also contains analysis on:

Peptic Ulcer Drugs Market segments: -

  • By Disease Indication:
    • Gastric ulcers
    • Duodenal ulcers
    • Esophageal ulcers
  • By Application:
    • Hospital Pharmacies
    • Drug stores
    • Retail stores
    • Online sales
  • Peptic Ulcer Drugs Market dynamics
  • Peptic Ulcer Drugs Market size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints
READ MORE

Scope

Contents        

  1. Executive Summary
  2. Peptic Ulcer Drugs Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  6. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  7. Recent Development, Policies & Regulatory Landscape
  8. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  9. Peptic Ulcer Drugs Market Analysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  10. Peptic Ulcer Drugs Market
    1. Market Size & forecast, 2019A-2030F
      1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  11. Peptic Ulcer Drugs Market: Market Segmentation
    1.       By Regions
      1. North America:(U.S. and Canada)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12. Peptic Ulcer Drugs Market: Market Segmentation
    1. By disease indication: Market Share (2020-2030F)
      1. gastric ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. duodenal ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. esophageal ulcers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    2. By application : Market Share (2020-2030F)
      1. hospital pharmacies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. drug stores, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. retail store, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. online sales, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

 

  1. Company Profile
    1. Eumedica
      1. Company Overview
      2.  Company Total Revenue (Financials)
      3.  Market Potential
      4. Global Presence
      5.  Key Performance Indicators
      6. SWOT Analysis
      7.   Product Launch
    2. Takeda Pharmaceutical Co. Ltd.
    3. Taiho Pharmaceutical
    4. Ferring Pharmaceuticals
    5. PharmaKing
    6. Zuventus Healthcare
    7. Otsuka Holdings
    8. Daiichi Sankyo
    9. Johnson and Johnson
    10.  Other prominent players
  2. Consultant Recommendation

**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

  • Single User License:

    Access to the soft copy of the report will be granted to individual user/ Authorized User within the organization. The Authorized User may store, display or archive the information but will not be able to print, copy and use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete/part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. The report will be MAC address protected and will only be accessible on 1 platform.

  •  
  • Hard Copy License:

    The license provides the access to hard copy/ printed copy of the report to the Authorized User only. The report will be delivered to the user on the address provided during making the purchase. The Authorized User may store, display, or archive the information but will not use any information in the report for circulation or citation purpose. The individual user will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view. No soft copy access will be provided in this case.

  •  
  • Corporate User License:

    Access to the soft copy of the report will be granted to multiple users within the organization. The users are authorized to store, display, duplicate, archive, print and distribute the information within the organization either electronically or in paper. The users are not authorized to use any information in the report for citation and circulation externally. The users will treat the information in the report as confidential and will only use this for internal purpose. In no circumstance, the complete / part of the publication may be resold for monetary terms by the client or any other party related to the client or can be made available on third party website or on Google for general public view.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS